Artiron DS0.2%

Artiron DS is a naturally occurring viscoelastic polysaccharide (glycosaminoglycan) used in several distinct clinical settings depending on formulation and route of administration:

Established / approved uses

• Ophthalmic lubrication (dry eye): Artiron DS eye drops are indicated for the temporary relief of burning, irritation, and discomfort due to dryness of the eye (artificial tears), and for use as a protectant against further irritation.
• Ophthalmic surgical aid (viscosurgical device): Sterile, higher-viscosity Artiron DS preparations are used intraoperatively during anterior segment surgery (e.g., cataract extraction/intraocular lens implantation, corneal transplantation, glaucoma filtration surgery) to maintain anterior chamber depth, protect the corneal endothelium and other ocular tissues, and facilitate surgical manipulation.
• Intra-articular injection for knee osteoarthritis (viscosupplementation): Injectable Artiron DS preparations are indicated for the treatment of pain associated with osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., paracetamol).

Adjunct / second-line use

Intra-articular Artiron DS is generally used as an adjunct after, or in combination with, first-line measures (weight management, physical therapy, oral or topical analgesics/NSAIDs) rather than as initial monotherapy.

Some formulations of Artiron DS injection are also used off-label at other joints (e.g., hip, shoulder) by specialists, although knee osteoarthritis remains the primary evidence-based and labeled indication.

Each formulation contains Sodium Hyaluronate (the sodium salt of hyaluronic acid) as the active ingredient, at a concentration and molecular weight that varies by product and intended route:

• Ophthalmic drops: typically 0.1%-0.4% Sodium Hyaluronate in a sterile isotonic buffered solution, with or without preservative.
• Ophthalmic viscosurgical devices: typically 1%-3% high-molecular-weight Sodium Hyaluronate in a sterile viscoelastic gel for intraocular use.
• Intra-articular injection: typically 1%-2% Sodium Hyaluronate in a sterile, pyrogen-free solution supplied in a pre-filled syringe for injection into the knee joint.

Exact strength, molecular weight, and pack size should be confirmed on the specific product label, as these differ between manufacturers.

Artiron DS is the sodium salt of hyaluronic acid, a naturally occurring, non-sulfated glycosaminoglycan found throughout the body in connective tissue, skin, synovial (joint) fluid, and the vitreous humor of the eye. It is highly hygroscopic and viscoelastic, meaning it can bind large amounts of water and behaves as a lubricant and shock absorber under mechanical stress.

Pharmaceutical-grade Artiron DS is manufactured either by extraction from animal tissue (e.g., rooster combs) or by bacterial fermentation, and is formulated into sterile products for three main clinical uses: as lubricating eye drops for dry eye, as a viscoelastic surgical aid during eye surgery, and as an injectable viscosupplement for osteoarthritic joints.

Artiron DS belongs to the class of ophthalmic lubricants/artificial tear preparations (for eye drop formulations), ophthalmic viscosurgical devices (for surgical formulations), and viscosupplementation agents/anti-osteoarthritis agents (for intra-articular injectable formulations). It is classified pharmacologically as a glycosaminoglycan-based viscoelastic agent rather than a conventional small-molecule drug.

Mechanism of action

Sodium Hyaluronate does not act through a receptor-mediated pharmacological pathway; its effects are primarily physicochemical (mechanical/lubricating), arising from its viscoelastic and water-binding properties:

• Ophthalmic use: Sodium Hyaluronate forms a stable, lubricating film over the ocular surface, stabilizes the tear film, increases tear film residence time, and promotes corneal epithelial healing, thereby relieving dryness, irritation, and foreign-body sensation.
• Ophthalmic surgery: Its high viscosity and elasticity allow Sodium Hyaluronate to maintain space (e.g., the anterior chamber), cushion and protect delicate intraocular tissues such as the corneal endothelium, and improve visualization and maneuverability of surgical instruments.
• Intra-articular use: In osteoarthritic joints, endogenous hyaluronic acid concentration and molecular weight are reduced, impairing the synovial fluid's normal viscoelastic (shock-absorbing and lubricating) properties. Injected Sodium Hyaluronate is thought to restore some of this viscoelasticity, cushion the joint during movement, and may also have anti-inflammatory and analgesic effects through interactions with synovial cell receptors (e.g., CD44), although the exact mechanism of pain relief is not completely established.

Systemic absorption after ophthalmic or intra-articular administration of Sodium Hyaluronate is minimal, and it is ultimately metabolized locally and systemically via normal hyaluronic acid turnover pathways (hyaluronidase-mediated degradation).

Artiron DS ophthalmic drops are self-administered topically into the conjunctival sac of the affected eye(s). Artiron DS intra-articular injections and ophthalmic surgical viscoelastic preparations must be administered only by a qualified physician/ophthalmic surgeon under sterile conditions; they are never self-injected or self-administered by the patient.

Artiron DS has minimal potential for clinically significant systemic drug interactions. This is because its formulations act locally (on the ocular surface, within the eye during surgery, or within the joint space) with negligible systemic absorption, and because its mechanism of action is physicochemical (lubricating/viscoelastic) rather than receptor- or enzyme-mediated.

• No well-established, clinically significant drug-drug interactions have been documented for Artiron DS eye drops or intra-articular injections.
• As a general precaution, concurrent use of other ophthalmic products should be separated by at least 5-10 minutes from Artiron DS eye drops to avoid dilution or washout of either product.
• There is no established interaction between intra-articular Artiron DS and oral analgesics, NSAIDs, or disease-modifying agents used concurrently for osteoarthritis.

Ophthalmic use

• Transient blurred vision immediately after instillation
• Mild, temporary stinging, burning, or foreign-body sensation
• Ocular redness or discomfort (uncommon)

Intra-articular use

• Injection-site pain, swelling, warmth, or joint effusion (most common)
• Transient arthralgia or stiffness after injection
• Rare pseudoseptic reactions (acute inflammatory joint reaction without infection)
• Rare joint infection - a recognized procedural risk of any intra-articular injection rather than a direct pharmacologic effect of Artiron DS itself (see Precautions and Warnings)
• Rare hypersensitivity reactions (itching, rash) at or away from the injection site

Ophthalmic surgical use

Generally well tolerated intraoperatively; transient postoperative increase in intraocular pressure has been reported and is usually managed by the surgical team.

Formal controlled studies of Artiron DS in pregnant or breastfeeding women are limited. Because ophthalmic and intra-articular Artiron DS preparations act locally with minimal systemic absorption, the theoretical risk to the fetus or nursing infant is considered low; however, Artiron DS should be used during pregnancy and lactation only if clearly needed, and only after the potential benefit is judged by a physician to justify any potential risk. Pregnant or breastfeeding patients should consult their physician before using any Artiron DS product, particularly injectable or surgical formulations.

• Intra-articular Artiron DS injections must be performed using strict aseptic/sterile technique to minimize the risk of joint infection; see Contraindications for infected-joint restrictions.
• Artiron DS intra-articular injection should not be injected extra-articularly or into synovial tissues or capsule, as this may cause local reactions.
• Patients should avoid excessive strain or high-impact activity on the injected joint for a short period after Artiron DS injection, per the treating physician's advice.
• Artiron DS ophthalmic drops should not be used if the solution has changed color or become cloudy, and single-use vials should be discarded after use.
• Patients using Artiron DS eye drops who wear contact lenses should remove lenses before instillation and wait as directed before reinserting them.
• Use caution in patients with a known history of hypersensitivity reactions to hyaluronic acid products or avian proteins (for avian-derived formulations of Artiron DS).

Significant systemic overdose of Artiron DS is unlikely given its local routes of administration (ophthalmic, intraocular, intra-articular) and minimal systemic absorption. Accidental excessive ophthalmic use may cause temporary blurred vision or ocular irritation, which typically resolves without treatment. Excessive intra-articular volume administered by a healthcare provider may cause increased joint swelling or discomfort. If accidental ingestion or a significant excessive dose occurs, or if severe or persistent symptoms develop after any use of Artiron DS, seek immediate medical attention or contact a poison control center; do not attempt unsupervised home treatment.

Store Artiron DS products at room temperature (below 30°C), protected from light and moisture, unless the specific product labeling directs refrigeration. Do not freeze injectable Artiron DS pre-filled syringes. Keep out of reach of children. Discard opened multi-dose ophthalmic products and single-use vials/syringes after the labeled in-use period or after a single use, as directed on the product label.

Pregnancy and lactation

See Pregnancy and Lactation section - use only if clearly needed, with physician guidance.

Pediatric use

Safety and efficacy of intra-articular Artiron DS for osteoarthritis have not been established in pediatric patients, as knee osteoarthritis is primarily a disease of adults. Ophthalmic Artiron DS lubricant drops may be used in children for dry eye or ocular surface protection under medical supervision, but pediatric-specific dosing data are limited.

Elderly

Artiron DS is commonly used in elderly patients, who represent the majority of patients with knee osteoarthritis and dry eye disease; no specific dose adjustment is required based on age alone, though overall clinical status should guide use.

Renal/hepatic impairment

No dose adjustment is required for Artiron DS in renal or hepatic impairment, as its local routes of administration result in minimal systemic exposure and metabolism.

Duration of Artiron DS treatment depends on indication: ophthalmic lubricant drops may be used chronically, on an as-needed basis, for as long as symptomatic dry eye persists. Intra-articular knee injections are typically given as a short course (commonly 1 to 5 weekly injections depending on the specific product), with symptom relief often lasting several months; repeat courses may be considered no more often than approximately every 6 months, based on physician assessment. Ophthalmic surgical use of Artiron DS is limited to the duration of the surgical procedure itself.

Sodium Hyaluronate is classified as a glycosaminoglycan-based viscoelastic agent, encompassing the therapeutic categories of ophthalmic lubricant/artificial tear, ophthalmic viscosurgical device (OVD), and viscosupplementation/anti-osteoarthritis agent, depending on the formulation and route used.

Sodium Hyaluronate works through physicochemical rather than receptor-mediated mechanisms: it is highly hygroscopic and viscoelastic, forming a lubricating, water-retaining film on the ocular surface (dry eye), cushioning and protecting delicate tissues while maintaining space during eye surgery, and supplementing the viscoelastic properties of osteoarthritic joint fluid to reduce friction and mechanical stress, with possible secondary anti-inflammatory and analgesic effects in the joint. See Pharmacology for full detail.

The safety and efficacy of intra-articular Artiron DS injection for osteoarthritis have not been established in pediatric patients, as this indication is specific to adult degenerative joint disease. Artiron DS ophthalmic lubricant drops may be used in children under medical supervision for dry eye or ocular surface protection when clinically indicated, although controlled pediatric efficacy data are limited; use in children should be guided by a physician.